- Home
- /
- News
- /
- Drug Trials
- /
- September 2009
Drug Trials News for September 2009
Orphan drug designation ensures market exclusivity for seven to ten years after market approval.
16 September, 2009
AstraZeneca recently announced results from the Phase III head-to-head trial PLATO that demonstrate that ticagrelor has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events, than clopidogrel.
08 September, 2009
Shire reported recently that it has completed its submission of a New Drug Application for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration.
04 September, 2009
Ablynx recently announced positive results from its Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor.
01 September, 2009